After being exposed as totally incorrect with your first attempt at refutation, you choose to attack in another manner with your normal obfuscation. Cred level continues to suffer.
Even if there is not a perfect correlation it would seem overall studies recently have tended to find an around 60-80% correlation between plasma Aß42/40 and global amyloid burden measured by PET (according to google gemini). Therefore I would says it is worth more than a "regulatory side note". It would be rather crazy for Anavex not to mention the differences with competition even if not a perfect comparison. Mayo noted on stocktwits that it did 73% better than Lecanemab at 52 weeks and about 60% better than Lecanemab score at week 72. So this wasn't a slim impovement even if only measuring something with a 70% odd correlation. Obv this is ignoring the other biomarker of brain volume loss reduction in blarcamesine in the dosed group vs placebo with a 5 in 10,000 chance of this being due to chance. The Mabs instead shrink the brain quicker than placebo.
News 
Market Data 
Discover 
